Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 8;12(8):1801.
doi: 10.3390/biomedicines12081801.

Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment

Mahesh Koirala  1 , Mario DiPaola  1
Affiliations
Review

Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment

Mahesh Koirala et al. Biomedicines. .

Abstract

Resistance to cancer drugs is a complex phenomenon that poses a significant challenge in the treatment of various malignancies. This review comprehensively explores cancer resistance mechanisms and discusses emerging strategies and modalities to overcome this obstacle. Many factors contribute to cancer resistance, including genetic mutations, activation of alternative signaling pathways, and alterations in the tumor microenvironment. Innovative approaches, such as targeted protein degradation, immunotherapy combinations, precision medicine, and novel drug delivery systems, hold promise for improving treatment outcomes. Understanding the intricacies of cancer resistance and leveraging innovative modalities are essential for advancing cancer therapy.

Keywords: PROTACs; SNIPERs; cancer drug resistance; combination therapies; immunotherapy combinations; novel drug delivery systems; precision medicine; targeted protein degradation.

PubMed Disclaimer

Conflict of interest statement

Author Mahesh Koirala is a consultant at Therabene Inc. as a Computational Scientist and does not hold any shares in the company. Mario DiPaola is an employee and shareholder of Therabene Inc.

Figures

Figure 1
Figure 1
Different modes of drug resistance.
Figure 2
Figure 2
Mechanism of PROTAC and protein degradation.
See this image and copyright information in PMC

References

    1. Li Y., He L.-R., Gao Y., Zhou N.-N., Liu Y., Zhou X.-K., Liu J.-F., Guan X.-Y., Ma N.-F., Xie D. CHD1L contributes to cisplatin resistance by upregulating the ABCB1–NF-κB axis in human non-small-cell lung cancer. Cell Death Dis. 2019;10:99. doi: 10.1038/s41419-019-1371-1. - DOI - PMC - PubMed
    1. Abu Samaan T.M., Samec M., Liskova A., Kubatka P., Büsselberg D. Paclitaxel’s mechanistic and clinical effects on breast cancer. Biomolecules. 2019;9:789. doi: 10.3390/biom9120789. - DOI - PMC - PubMed
    1. Longley D., Johnston P. Molecular mechanisms of drug resistance. J. Pathol. J. Pathol. Soc. Great Br. Irel. 2005;205:275–292. doi: 10.1002/path.1706. - DOI - PubMed
    1. Vasan N., Baselga J., Hyman D.M. A view on drug resistance in cancer. Nature. 2019;575:299–309. doi: 10.1038/s41586-019-1730-1. - DOI - PMC - PubMed
    1. Holohan C., Van Schaeybroeck S., Longley D.B., Johnston P.G. Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer. 2013;13:714–726. doi: 10.1038/nrc3599. - DOI - PubMed

LinkOut - more resources